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Objective. This study was performed to determine the prevalence of and associated risk factors for cardiovascular disease (CVD)
in Latin American (LA) patients with systemic lupus erythematosus (SLE). Methods. First, a cross-sectional analytical study was
conducted in 310 Colombian patients with SLE in whom CVD was assessed. Associated factors were examined by multivariate
regression analyses. Second, a systematic review of the literature on CVD in SLE in LA was performed. Results. There were 133
(36.5%) Colombian SLE patients with CVD. Dyslipidemia, smoking, coffee consumption, and pleural effusion were positively
associated with CVD. An independent effect of coffee consumption and cigarette on CVD was found regardless of gender and
duration of disease. In the systematic review, 60 articles fulfilling the eligibility criteria were included. A wide range of CVD
prevalence was found (4%–79.5%). Several studies reported ancestry, genetic factors, and polyautoimmunity as novel risk factors
for such a condition. Conclusions. A high rate of CVD is observed in LA patients with SLE. Awareness of the observed risk factors
should encourage preventive population strategies for CVD in patients with SLE aimed at facilitating the suppression of cigarette
smoking and coffee consumption as well as at the tight control of dyslipidemia and other modifiable risk factors.
1. Introduction
Systemic lupus erythematosus (SLE) is a complex systemic
autoimmune disease (AD), characterized by the production
of numerous pathogenic autoantibodies [1]. Diverse heri-
table, hormonal, and environmental factors and immune-
system aberrations contribute to the clinical expression of
the disease [2]. The heterogeneous nature of SLE explains
the broad spectrum of clinical manifestations (i.e., subphe-
notypes). SLE affects predominantly women (female-to-male
ratio 9 : 1) of child-bearing age [3]. The annual incidence and
prevalence range from 1.4 to 11 cases per 100,000 population,
and from 7.4 to 159.4 cases per 100,000 population, respec-
tively [4] depending on a variety of factors, including age,
gender, and ancestry. African, Hispanic, and Asian ancestry
significantly influence both the risk of developing the dis-
order and outcome [4]. A bimodal mortality was described
by Urowitz et al. [5] characterized by an early peak in the
first 3 years after diagnosis due to active disease, infections
and glomerulonephritis, and a second peak, 4–20 years after
SLE diagnosis, in which cardiovascular disease (CVD) is the
main feature and cause of death. Although overall mortality
for patients with SLE has improved over the past 30 years,
mortality due to CVD has remained almost the same [6].
CVD is the leading cause of mortality, responsible for
about 30% of deaths worldwide. Globally, 80% of total CVD
deaths occur in developing countries [7]. In addition, there
is strong epidemiologic evidence that CVD risk among
SLE patients compared to the general population is at least
doubled [8]. Noteworthy, the excessive cardiovascular (CV)
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events observed in SLE individuals are not fully explained
by classic risk factors. Several SLE-specific factors, including
disease activity and duration, and possibly specific manifes-
tations and therapies, further increase CV risk [8]. In fact,
SLE per se seems to be an independent risk factor for the
development of accelerated atherosclerosis [9].
SLE is not uncommon in Latin America (LA), the
geographical area defined byMexico, Central America, South
America, and the islands of the Caribbean, a rapidly grow-
ing region with almost 600 million inhabitants [10]. Latin
Americans are considered a highly admixed population due
to a mixed ethnicity (so called mestizos) that is mainly
derived from a European and Amerindian inheritance [11].
The increased prevalence of chronic diseases in LA has
been attributed to diverse causes including the ageing of the
population and lifestyle factors such as smoking, physical
inactivity, and excess alcohol intake [12]. Despite important
advances in recent decades, LA remains one of the world’s
most unequal regions [13]. Enormous cultural differences in
health perceptions in LA exist, correlating with individuals’
economic and health conditions [12]. So far, some studies
regarding SLE have documented differences in health status,
disease prevalence, treatment outcomes, and healthcare use
among different ethnic groups, suggesting that minorities
influence SLE health disparities [14–19]. Thus, this study was
performed to determine the prevalence and associated risk
factors for CVD in Latin American patients with SLE.
2. Material and Methods
2.1. Study Population. First, a cross-sectional analytical study
was conducted in 310 Colombian patients with SLE in whom
CVD was assessed. The subjects were seen at the Center for
Autoimmune Diseases Research (CREA) in Bogota, Colom-
bia. All of them fulfilled the 1997 update American College of
Rheumatology classification criteria for SLE [20]. This study
was done in compliance with Act 008430/1993 byMinistry of
Health of the Republic of Colombia, which classified it as a
minimal-risk research. The institutional review board of the
Universidad del Rosario approved the study design.
Information on patient socio-demographic and cumula-
tive clinical and laboratory data, as well as household descrip-
tion, were obtained by interview, standardized report form,
physical examination and chart review. All data were col-
lected in an electronic and secure database. Socio-demo-
graphic variables included age at SLE onset, disease duration,
educational and socioeconomic status, current occupation,
smoking habits, coffee consumption, expositional factors and
physical activity. Age at onset of the disease was defined as the
first subjective experience of the symptom(s) and/or sign(s)
described in any of the items of the classification criteria
[21]. Duration of disease was considered as the difference
between age at onset and the date of first participation in
the study. Educational level was recorded as the number of
years of education and was divided into two groups (more
or less than 9 years) of education based on the “General Law
of Education” in Colombia [22, 23]. Socioeconomic status
was categorized on the basis of national legislation and was
divided into low (1 and 2) and high (3–6) status. Smoking
habits was assessed as ever; 1–6, 6–15, and >15 packages/year;
or quitter cigarette consumption. Coffee intake was asked
as yes or not, and measured in cups per day (1-2, 2–4, >4).
Several expositional factors were also questioned, including
the use of silicone implants, hair dyes, pesticides and organic
solvents [24].
2.2. Clinical Variables. Clinical and laboratory variables were
registered as present or absent at any time during the
course of the disease. Clinical features of the disease were
included taking into account the revised American College
of Rheumatology criteria [20] and others manifestations as
follows: polyautoimmunity (coexistence of an additional AD
in the same individual on the basis of international criteria)
[25, 26], multiple autoimmune syndrome (presence of more
than two AD in the same patient) [26–28]; familial autoim-
munity, and familial autoimmune disease were also registered
as the presence of any other AD and SLE in first degree rela-
tives (FDR) respectively [27–29]. Regarding pharmacological
treatment, current or past use of azathioprine, mycopheno-
late mofetil, cyclophosphamide, methotrexate, antimalarials
(i.e., clhoroquine, hydroxychloroquine), glucocorticoids (i.e.,
prednisolone, metilprednisolone, and deflazacort), and bio-
logical therapy (i.e., Rituximab) were recorded.
2.3. Cardiovascular Assessment. Five subphenotypes were
defined and assessed: first, hypertension, defined as having a
blood pressure≥140/90mmHgor using any antihypertensive
medication [30]: systolic and diastolic blood pressures were
measured twicewith at least a 15-minute interval between and
the averages were recorded. Second, history of stroke, third,
coronary event (i.e., unstable angina, myocardial infarction
(MI)), fourth, thrombotic event (other than coronary disease
and carotid involvement, requiring anticoagulant treatment),
fifth, carotid disease (doppler criteria or intima-media thick-
ness ≥0.9).
2.4. Laboratories Measurements. Relevant laboratory vari-
ables associated with SLE were recorded. Antinuclear anti-
bodies, antidouble strandDNAantibodies, precipitating anti-
bodies to extractable nuclear antigens (Sm, U1-RNP, Ro/SS-
A, La/SS-B), anticardiolipin IgG and IgM, antibeta 2-glyco-
protein 1 IgG and IgM antibodies, and lupus anticoagulant
were extracted from the patient’s clinical record. Other
autoantibodies including rheumatoid factor, anticyclic cit-
rullinated peptide, -thyroperoxidase enzyme, -thyroglobulin,
-Scl 70, -centromere, -mitochondrial, and -smooth muscle
antibodies were also recorded. Inflammatory biomarkers,
including erythrocyte sedimentation rate (ESR), and serum
high sensitive C-reactive protein (CRP) levels, as well as
white blood cell and platelet count, hemoglobin levels, mean
corpuscular volume, coombs test, complement (i.e., C3 and
C4 levels), TSH, tetraiodothyronine T4, venereal disease
research laboratory, and creatinine were extracted from
patient’s clinical record. Likewise, serum levels of total cho-
lesterol (TC), triglycerides (TGL), high-density lipopro-
tein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), and glycemia were determined by blood tests pro-
vided by every patient.
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2.5. Assessment of Traditional Risk Factors for CVD. Patients
were assessed for traditional CVD risk factors including
current age (≥45 and ≥55 years for men and women, resp.)
[31–34]. Type 2 diabetes mellitus (T2DM) was defined as
having a fasting plasma glucose level≥7mmol/L (126mg/dL),
or taking any antidiabetic agents at the time of assessment
[35]. A diagnosis of dyslipidemia was given if the patient had
(a) hypercholesterolemia, defined as taking lipid-lowering
medication as a surrogate, or having a fasting plasma TC
≥200mg/dL (b) HDL ≤40mg/dL, (c) hypertriglyceridemia
(TGL ≥150mg/dL), or (d) elevated LDL (≥100mg/dL) [31,
36]. Current hemoglobin ≤12 g/dL established a diagnosis of
anemia and current levels of creatinine (abnormal defined
as ≥1.2mg/dL) were evaluated as well. History of premature
CAD in FDR was also assessed [37]. Patients and their past
medical records were evaluated for the current or past use of
aspirin or hormone replacement therapy.
2.6. Statistical Analysis. First, univariate analyses were
done. Categorical variables were analyzed by frequencies.
Kolmogorov-Smirnov normality test was done to evaluate
normality for quantitative continuous variables. Parametric
data are expressed as the mean and standard deviation,
and nonparametric data are described as the median and
interquartile range. Second, associations between traditional
and nontraditional CVD risk factors were assessed by
bivariate analyses.Thepresence ofCVDwas assessed through
chi square tests or Fisher’s exact tests when the variable was
dichotomous. Parametric values were analyzed by 𝑡 student
test. Nonparametric values were analyzed by Mann-Whitney
𝑈 test. Clinical variables with a 𝑃 ≤ 0.25 were included in a
multivariable model. Finally, a multivariate binomial logistic
regression model having CVD as the dependent variable was
fit. As independent factors, themodel included the traditional
and nontraditional associations that were statistically signif-
icant in bivariate analyses and those variables that were bio-
logically plausible.Moreover, other logistic regressionmodels
were made, including interactions between independent
factors. In both circumstances, the models were adjusted by
gender and duration of the disease. Adequacies of logistic
models were assessed using the Hosmer-Lemeshow good-
ness-of-fit test. The Nagelkerke 𝑅2 (i.e., pseudo-𝑅2) was used
to estimate the percentage of variance explained by the mod-
els. Adjusted odds ratios (AOR) were calculated with 95%
confidence intervals (CI). The Wald statistic test was used
to evaluate the significance of individual logistic regression
coefficients for each independent variable. Statistical analyses
were done by the Statistical Package for the Social Sciences
(SPSS, v.20, Chicago, IL, USA).
2.7. Systematic Review of Literature. The Preferred reporting
items for Systematic Reviews and Meta-analyses guidelines
were followed [38] to systematically search in the following
databases: PubMed, EMBASE, Scopus, SciELO, and Virtual
Health Library—which includes BIREME, LILACS andmany
others LA sources—about CVD and SLE in LA population.
Three reviewers did the search and extraction data indepen-
dently (AAJC, SMJC, and CMJ) using predefined eligibility
criteria, from inception up to February 2013.
The search was done in PubMed, using the following
Medical Subject Headings (MeSH terms) groups: “Lupus
Erythematosus, Systemic,” “Cardiovascular Diseases;” “Latin
America,” “Ethnic Groups,” “Brazil,” “Mexico,” “Colombia,”
“Chile,” “Cuba,” “Panama,” “Venezuela,” “Bolivia,” “Peru,”
“Argentina,” “Uruguay,” “Paraguay,” “Ecuador,” “Nicaragua,”
“Surinam,” “French Guiana,” “Guatemala,” “Honduras,”
“Belize,” “Costa Rica,” “El Salvador,” “Puerto Rico,” “Domini-
can Republic,” and “Haiti.” Each one of them was cross-
referenced with the following MeSH terms/keywords: “risk
factors,” “traditional risk factors,” “classic risk factors,” “non-
traditional risk factors,” “novel risk factors,” “hypertension,”
“metabolic syndrome,“ “obesity,” “smoking,” “tobacco,” “dys-
lipidemia,” “advanced age,” “menopausal status,” “family his-
tory of CVD,” “hyperhomocysteinemia,” “sedentary lifestyle,”
“renal impairment,” “male gender,” “type 2 diabetes mellitus,”
“insulin resistance,” “hormone replacement therapy,” “coffee,”
“ancestry,” “polymorphism, genetic,” “poliautoimmunity,”
“autoantibodies,” “antibodies, antiphospholipid,” “lupus
coagulation inhibitor,” “circulation anticoagulants,” “anti-
bodies, anticardiolipins,” ”beta 2-glycoprotein I,” “endothelial
cells antibodies,” “systemic inflammation,” “c-reactive
protein,” “blood sedimentation,” “tumor necrosis factor,”
“cytokines,” “immune complex,” “disease activity,” “SLEDAI,”
“organ damage,” “SDI,” “duration of illness,” “immune
cells aberrations,” “glucocorticoids,” “steroids,” “DMARD,”
“antirheumatic agents,” “methotrexate,” “biological therapy,”
“rituximab,” “anti-Inflammatory agents, non-steroidal,”
“azathioprine,” “vasculopathy,” “lupus nephritis,” “premature
menopause,” “endogenous dyslipidemia,” “sociodemographic
factors,” “hypovitaminosis D,” “vitamin D deficiency,” “low
vitamin D,” “osteoporosis,” “biomarkers,” “antiphospholipid
syndrome,” “thyroiditis, autoimmune,” “Graves Disease,”
“Hashimoto Disease,” “scleroderma,” “Sjo¨gren’s syndrome,”
“rheumatoid arthritis,” ”hypertension,” “ischemic heart dis-
ease,” “coronary artery disease,” “acute coronary syndrome,”
“congestive heart failure,” “myocardial infarction,” “stroke,”
“angina,” “thrombosis,” “deep vein thromboses,” “pulmonary
embolism,” “periphery arterial disease,” and “atherosclerosis.”
Each term was cross-referenced for the greatest number of
results. No limits regarding language, period of publication,
or publication type were used.
The same terms were used for searching in EMBASE
and Scopus databases. Each MeSH term and keyword was
translated into DeCS (Health Sciences Descriptors) in order
to explore sources of information in Spanish, Portuguese,
and English through SciELO and Virtual Health Library
databases.
2.8. Study Selection, Data Extraction, and Quality Assessment.
Reviewers screened all titles and abstracts and applied the
eligibility criteria in order to identify studies that were
appropriate for inclusion [39]. A study was included if (a)
the abstract was available, (b) it contained original data, (c) it
used accepted classification criteria for SLE, (d) it measured
CV risk factors (traditional and/or nontraditional), (e) it
examined as a clinical endpoints: hypertension, ischemic
heart disease (IHD), coronary artery disease (CAD), acute
coronary syndrome (ACS), MI, angina, congestive heart
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failure (CHF), stroke, thrombosis, peripheral arterial disease
(PAD), and subclinical atherosclerosis, and (d) it includes
LA population. In order to complete the systematic review,
several authors were contacted by E-mail for full text and
those references from the articles that seemed to be relevant
to the review were hand-searched.
Articles were excluded from the analysis if they dealt
with juvenile SLE or were done on animal models (i.e.,
murine models) instead of SLE patients. Studies were also
excluded if they were reviews or case reports, or if they
discussed topics not related to CVD, and/or were not done on
LA population. Blinded reviewers (AAJC, SMJC, and MJC)
organized selected articles on the basis of publication source,
country, author, year, type of study, sample size, traditional
and nontraditional risk factors, cardiovascular outcomes eva-
luated, and main results. Only novel risk factors with sta-
tistical significance were included. For details, see Supple-
mentary Table S1 in the supplementary material available
online at http://dx.doi.org/10.1155/2013/794383. Each record
was classified based on the quality score of the studies that
was assigned by applying the levels established by the Oxford
Centre for Evidence-basedMedicine 2011 in order to evaluate
the risk of bias [40]. The search results were compared and
disagreements were resolved by consensus.
3. Results
3.1. Description of the Study Population. Out of a total of
310 patients, 91.3% (283/310) were women. The median
(interquartile range) of age and duration of the disease was 37
(22) and 5 (9) years, respectively. CVDwas observed in 36.5%
(113/310). The most frequent condition was hypertension
(25.2%) (Tables 1 and 2).
3.2. Factors Associated with CVD. Current age, ever smok-
ing, coffee consumption, polyautoimmunity (i.e., antiphos-
pholipid syndrome), dyslipidemia, use of cytotoxic drugs,
serositis, renal involvement (i.e., nephrotic syndrome), and
thrombocytopenia were all risk factors significantly asso-
ciated with CVD. Instead, ethnicity and leukopenia were
factors negatively associated with CVD (Table 3).
3.3. Adjusted Effects of Risk Factors for CVD. Dyslipidemia,
pleural effusion, polyautoimmunity, and renal compromise
were variables significantly associated with CVD, regardless
of gender and duration of the disease by logistic regression
analysis (Table 4). The association between CVD and smok-
ing habit remained statistically significant after establishing
interaction with coffee consumption (Table 5).
3.4. Systematic Literature Review. There were 21,161 arti-
cles identified in PubMed, EMBASE, and Scopus databases
search. Additional records identified through other sources
included 814 articles (SciELO and Virtual Health Library).
Therefore, the database searches provided a total of 21,975
publications. Of these, 19,729 were identified as duplicates.
A total of 2,246 full text articles were assessed for eligibility.
Only 115 articles were included for methodological analysis.
Table 1: Demographic and clinical characteristics of 310 patients
with SLE.
Characteristic Median (IQR)
Age (y) 37 (22)
Duration of disease (y) 5.0 (9.0)
Characteristic Mean (SD)
Age at SLE onset (y) 38 (15.4)
Age of diagnosis (y) 39.8 (15.8)
Sociodemographic characteristic % (𝑛/𝑁)
Female 91.3 (283/310)
High education level 85.6 (255/298)
High socioeconomic status 79.5 (236/297)
Mixed occupation 23.2 (71/306)
Housewife 21.2 (65/306)
Exposure to hair dyes 40.6 (125/308)
Clinical manifestation % (𝑛/𝑁)
Cutaneous compromise 88.1 (273/310)
Arthropathy 87.7 (272/310)
Neurological involvement 10 (31/310)
Hematological criteria 34.5 (107/310)
Immunological criteria 78.1 (242/310)
Raynaud’s phenomenon 39.4 (122/310)
Vasculitis 18.4 (57/310)
Alopecia 47.7 (148/310)
Livedo reticularis 19 (59/310)
Pleural effusion 23.5 (73/310)
Pulmonary hypertension 6.5 (20/310)
Pulmonary embolism 2.9 (9/310)
Pericarditis 14.5 (45/310)
Lupus nephritis 46.5 (144/310)
Nephritic syndrome 5.5 (17/310)
Nephrotic syndrome 16.8 (58/310)
Histological pattern
Normal 8.5 (7/82)
Mesangial glomerulonephritis 15.9 (13/82)
Focal segmental glomerulonephritis 13.4 (11/82)
Proliferative glomerulonephritis 41.5 (34/82)
Membranous glomerulonephritis 11 (9/82)
Autoimmune disease(s) % (𝑛/𝑁)
Polyautoimmunity 26.1 (81/310)
MAS 6.1 (19/310)
Familial autoimmunity in FDR 30.3 (94/310)
RA 3.9 (12/310)
APS 8.7 (27/310)
SS 8.7 (27/310)
AITD 6.8 (21/310)
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Table 1: Continued.
Characteristic Median (IQR)
Comorbidities % (𝑛/𝑁)
Fibromyalgia 9.7 (30/309)
Depression 21.4 (66/309)
Epilepsy 3.9 (12/309)
Peptic ulcer disease 38.5 (119/309)
Anemia 8.1 (25/309)
Osteoporosis 5.8 (18/309)
Malaria 2.3 (7/303)
Hepatitis A 7.1 (22/309)
Miscarriage 20.2 (57/282)
Drugs % (𝑛/𝑁)
Azathioprine 33.9 (105/310)
Antimalarial 80.6 (250/310)
Mycophenolate Mofetil 15.8 (49/310)
Steroid 78.4 (243/310)
Rituximab 7.4 (23/310)
Cytotoxic agents 12.3 (38/310)
Biological treatment 8.4 (26/310)
Methotrexate 34.8 (108/310)
Laboratories findings % (𝑛/𝑁)
Anemia 25.9 (76/293)
Leukopenia 38 (114/300)
Lymphopenia 78.7 (85/202)
Thrombocytopenia 7.8 (23/296)
C-reactive protein (+) 35.4 (57/161)
Erythrocyte sedimentation rate (+) 46.2 (104/225)
VDRL (+) 24.5 (26/204)
Abnormal serum creatinine 9.7 (26/268)
Abnormal creatinine clearance 56.6 (94/166)
24 hours proteinuria (+) 37.7 (80/212)
Hematuria 57.4 (58/101)
Pyuria 36.1 (56/155)
Antinuclear antibodies (+) 98.6 (287/291)
Lupus anticoagulant (+) 51 (52/102)
Anti-dsDNA antibodies (+) 54.6 (147/269)
Low complement 3 (C3) 60.8 (160/263)
Low complement 4 (C4) 31.4 (83/264)
aCL IgG (+) 33.8 (79/234)
aCL IgM (+) 32.4 (73/225)
Beta 2-glycoprotein antibodies IgG (+) 29.4 (10/34)
Beta 2-glycoprotein antibodies IgM (+) 28.6 (6/21)
Anti-Ro antibodies (+) 48.6 (122/251)
Anti-La antibodies (+) 26.2 (64/244)
Anti-Sm antibodies (+) 36 (89/247)
Anti-RNP antibodies (+) 46 (109/237)
Table 1: Continued.
Characteristic Median (IQR)
Rheumatoid factor (+) 34.6 (27/78)
Citrullinated peptide antibodies (+) 34.3 (12/35)
Thyroid stimulating hormone (+) 51.5 (53/207)
Thyroid peroxidase antibodies (+) 38.6 (17/44)
Thyroglobulin antibodies (+) 20 (6/30)
CVD: cardiovascular disease; SLE: systemic lupus erythematosus; IQR:
interquartile range; SD: standard deviation; Y: years; MAS: multiple autoim-
mune syndrome; FDR: first-degree relatives; RA: rheumatoid arthritis; APS:
antiphospholipid syndrome; SS: Sjo¨gren’s syndrome; AITD: autoimmune
thyroid disease; VDRL: venereal disease research laboratory; aCL: anticardi-
olipin antibodies.
Arthropathy was defined as the presence of at least one of the following:
arthritis, arthralgia, hands edema, or Jaccoud’s arthropathy.
Cutaneous compromise was defined as the presence of at least one of the
following: photosensitivity, oral ulcers, malar rash, discoid lupus, subacute
lupus, and urticaria.
Neurological involvement were defined as the presence of at least one of the
following: seizures, psychosis, and peripheral nerve compromise.
Hematological criteria were defined as the presence of at least one of the
following: hemolytic anemia, leukopenia, lymphopenia, and thrombocy-
topenia.
Immunological criteria were defined as the presence of at least one of the
following: anti-dsDNA, anti-Sm, anticardiolipin IgG or IgM, lupus anti-
coagulant, false-positive test VDRL, or fluorescent treponemal antibody
absorption test.
Finally, 60 articles that had interpretable data and fulfilled the
eligibility criteria were included. In 3 papers, data extraction
was made from abstract [41–43]. For details, see Supplemen-
tary Table S1. There were 29 from Brazil [42, 44–71], 14 from
Mexico [43, 72–84], 6 from United States of America [16–
18, 85–87], 5 from Argentina [14, 41, 88–90], 4 from Puerto
Rico [91–94], and 1 from Colombia [95] and Chile [96]. Five
studies correspond to SLE LUMINA (LUpus in MInorities:
nature versus nurture) multiethnic cohort [16–18, 85, 86].
The LUMINA cohort is comprised of patients of Hispanic
(from Texas and Puerto Rico), African-American and Cau-
casian background. Two studies correspond to GLADEL’S
(Grupo LatinoAmericanoDe Estudio de Lupus) longitudinal
inception cohort [14, 97]. Thirty studies were cross-sectional,
15 were case-controls, 11 were cohort, 2 nested case-control
and 2 were an inception cohort. The flowchart for systematic
literature review and articles included in the analysis are
shown in Figure 1.
3.5. Prevalence, Risk Factors, and Subphenotypes of CVD. Out
of total of 60 articles that fulfilled eligibility criteria, 46 had
interpretable data regarding CVD frequency, which corre-
sponds to a prevalence range of 4%–79.5%. Several classic
CV risk factors such as metabolic syndrome (MetS), obesity,
dyslipidemia, hypertension, T2DM, sedentary lifestyle, male
gender, smoking, advanced age, hyperhomocysteinemia,
renal impairment, family history of CVD, and menopausal
status were described. Several studies reported nontraditional
risk factors such as ancestry, certain single-nucleotide poly-
morphisms, SLE per se, polyautoimmunity, autoantibodies
(i.e., antiphospholipid), markers of systemic inflammation
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Table 2: Cardiovascular disease characteristics of 310 patients with
SLE.
% (𝑛/𝑁)
Clinical manifestation
Cardiovascular disease 36.5 (113/310)
Hypertension 25.2 (78/310)
Stroke 16.8 (52/310)
Coronary disease 2.6 (8/310)
Thrombotic event 1.6 (5/310)
Carotid disease 0.6 (2/310)
Risk factors
Type 2 diabetes mellitus 1.9 (6/309)
Dyslipidemia 18.1 (56/309)
Ever smoking 39.21 (120/306)
1 to 6 packages/year 4.2 (13/306)
6 to 15 packages/year 2.6 (8/306)
More than 15 packages/year 2.3 (7/306)
Quitter 30.1 (92/306)
Coffee consumption 61.5 (187/304)
1 to 2 cups/day 30.9 (94/304)
2 to 4 cups/day 22.7 (69/304)
More than 4 cups/day 7.9 (24/304)
Never 38.5 (117/304)
Laboratories findings
Abnormal triglycerides 34.3 (12/35)
Abnormal total cholesterol 44.4 (16/22)
Abnormal high-density cholesterol 58.8 (20/34)
Abnormal low-density cholesterol 33.3 (8/24)
Abnormal glycemic 25.7 (9/35)
(i.e., CRP), SLE disease activity, SLE duration, organ damage,
immune cells aberrations, medication (i.e., glucocorticoids),
vasculopathy, lupus nephritis, endogenous dyslipidemia,
bone mineral density, education level, and monthly income.
A broad spectrum of CV subphenotypes including hyperten-
sion, IHD, CAD, ACS, MI, angina, CHF, stroke, thrombosis,
peripheral arterial disease, subclinical atherosclerosis, and
mortality due to CVD were described in LA individuals with
SLE. For details, see Figure 2 and Supplementary Table S1.
4. Discussion
The analysis of Colombian patients with SLE discloses a high
prevalence of CVD (36.5%). In contrast, prospective North
Americans cohort studies showed a prevalence and annual
incidence of CVD between 6 and 10%, and 1.5%, respectively
[9, 98, 99]. Meanwhile, a case control study on the British
General Practice Research Database showed higher risk
of CVD in patients with SLE than rheumatoid arthritis
[100]. Furthermore, in Italian population, Doria et al. [101]
demonstrated rates of 10–40% for subclinical atherosclerosis.
This inconsistencymay reflect methodological obstacles such
as differences in the definition of CVD outcome. Since
CVD begins by endothelial dysfunction, hypertension was
considered as the first subphenotype to be assessed.
4.1. Epidemiology of Atherosclerosis among Patients with SLE.
Carotid plaque is prevalent in 21% of SLE patients under
age of 35 and in up to 100% of those over age 65 [102]. The
most striking example of raised risk of MI comes from the
University of Pittsburgh SLE cohort, in which women with
SLE aged 35–44 were >50 times more likely to experience MI
than women without SLE from the Framingham Offspring
study (RR 52.4; 95% CI 21.6–98.5) [8, 98].
Independent predictive risk factors for CV events had
been assessed in five large prospective cohorts of patientswith
SLE, including Baltimore (1992, 𝑛 = 229) [103], Pittsburg
(1997, 𝑛 = 498) [98], LUMINA (2004, 𝑛 = 546) [17], Toronto
(2007, 𝑛 = 561) [104] and Systemic Lupus International
Collaborating Clinics-Registry for Atherosclerosis (2010, 𝑛 =
637) [105]. These cohorts found association of diverse classic
risk factors (i.e., older age at diagnosis, smoking, hyperc-
holesterolemia, male gender, and hypertension), as well as
novel risk factors (i.e., longer duration of SLE and glucocor-
ticoid use, antiphospholipid antibodies, and neuropsychiatric
lupus), with CVD in SLE patients [105, 106]. In a recent meta-
analysis, Schoenfeld et al. [8] showed that epidemiologic
data strongly support that SLE patients are at elevated
relative risk of CVD. The risks of MI, CHF, CVA, and CVD
mortality are all increased among SLE patients compared to
general population risks.The variability regarding the relative
importance of risk factors for CVD among SLE patients in
past epidemiologic studies is likely due in part to different
designmethods and different patient and comparison groups.
4.2. CVD in Hispanics with SLE. CVD has been assessed
in LUMINA multiethnic cohort and GLADEL’s longitudinal
inception cohort, which demonstrated differences in sociode-
mographic, clinical (i.e., subphenotypes), immunologic, and
therapeutic characteristics, in SLE patients with CV events
[14–19, 85, 86, 93]. The present study adds further evidence
about the high frequency of CVD in patients with SLE,
their traditional risk factors (i.e., dyslipidemia, and smoking),
and highlights coffee consumption as a factor for such a
complication. Through the systematic review several factors
and outcomes related to CVD were also identified (Table 6).
4.3. Cigarette Smoking and Coffee Consumption Independently
Influence the Risk of Developing CVD. Several studies have
assessed smoking as an independent risk factor for CV
atherosclerotic disease [17, 107–111]. Gustafsson et al. [110]
found that smoking may be the main traditional risk factor
promoting increased CV risk in 208 SLE patients (RR 3.4,
95% CI 1.3–9.2). Previously, the same group found that
smoking was predictive of MI, stroke, peripheral vascular
disease (PVD) or CV mortality among the same patient
population [109]. Toloza et al. [17] prospectively followed
SLE patients over a median follow-up of 73.8 months and
compared those who had a CVD event to those who did
not as part of the LUMINA study. Current cigarette use was
significantly associated with a 3.7-times increased risk of
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Table 3: Characteristics associated with CVD in 310 patients with SLE.
Characteristic
Cardiovascular Noncardiovascular
OR (95% CI) 𝑃disease 113/310 disease 197/310
% (𝑛/𝑁) % (𝑛/𝑁)
Sociodemographic characteristic
Age (y) Median (IQR): 40 (23) Median (IQR): 36 (21) 0.059
Age at SLE onset (y) Median (IQR): 30 (19) Median (IQR): 26 (18) 0.175
Age of diagnosis (y) Median (IQR): 34 (22) Median (IQR): 28 (18) 0.041
Ever smoking 50.9 (57/112) 37.1 (73/194) 1.75 (1.09–2.61) 0.019
Coffee 70.5 (79/112) 55.2 (108/192) 1.94 (1.19–3.18) 0.009
Hair dye 46 (52/113) 37.4 (73/195) 1.42 (0.89–2.29) 0.139
Pesticides 3.5 (4/113) 1 (2/197) 3.56 (0.64–19.75) 0.122
Autoimmune disease(s)
MAS 3.5 (4/113) 7.1 (14/197) 0.48 (0.15–1.49) 0.196
Familial autoimmunity in FDR 19.5 (22/113) 25.4 (50/197) 0.71 (0.40–1.25) 0.235
RA 0.9 (1/113) 5.6 (11/197) 0.15 (0.01–1.19) 0.062
APS 16.8 (19/113) 4.1 (8/197) 4.77 (2.01–11.31) 0.0001
AITD 4.4 (5/113) 9.1 (16/197) 0.52 (0.18–1.47) 0.213
Comorbidities
Type 2 diabetes mellitus 3.5 (4/113) 1 (2/197) 3.56 (0.64–19.75) 0.196
Dyslipidemia 28.3 (32/113) 12.2 (24/197) 2.83 (1.56–5.11) 0.0001
Fibromyalgia 14.2 (16/113) 7.1 (14/197) 2.14 (1.00–4.57) 0.045
Treatment
Antimalarials 77 (87/113) 82.7 (163/197) 0.69 (0.39–1.23) 0.217
Mycophenolate Mofetil 19.5 (22/113) 13.7 (27/197) 1.52 (0.82–2.82) 0.181
Cytotoxics agents 17.7 (20/113) 9.1 (16/197) 2.13 (1.07–4.23) 0.027
Clinical variable
Discoid lupus 5.3 (6/113) 9.1 (16/197) 0.55 (0.21–1.44) 0.225
Alopecia 41.5 (47/113) 51.3 (101/197) 0.67 (0.42–1.08) 0.101
Subacute 6.2 (7/113) 3 (6/197) 2.10 (0.68–6.41) 0.239
Urticaria 19.5 (22) 10.2 (20/197) 2.14 (1.11–4.12) 0.021
Vasculitis 15 (17/113) 20.3 (40/197) 0.89 (0.37–1.29) 0.250
Neurological involvement 13.3 (15/113) 8.1 (16/197) 1.73 (0.82–3.65) 0.146
Headache 28.2 (33/113) 18.9 (37/197) 1.79 (1.03–3.06) 0.035
Psychosis 7.1 (8/113) 3.8 (7/197) 2.08 (0.72–5.86) 0.164
Serositis 37.2 (42/113) 23.9 (47/197) 1.88 (1.14–3.12) 0.013
Pleural effusion 31.9 (36/113) 18.9 (37/197) 2.02 (1.18–3.44) 0.009
Hands edema 32.7 (37/113) 15.9 (33/197) 2.41 (1.40–4.16) 0.0001
Renal involvement 56.6 (84/113) 40.9 (80/197) 1.91 (1.19–3.05) 0.006
Nephrotic 27.4 (31/113) 10.7 (21/197) 3.16 (1.71–5.84) 0.0001
Pulmonary haemorrhage 3.5 (4/113) 0.5 (1/197) 7.19 (0.79–65.16) 0.061
Laboratory findings
Thrombocytopenia 11.9 (13/109) 5.3 (10/187) 2.39 (1.01–5.67) 0.041
Leukopenia 30.6 (34/111) 42.3 (80/189) 0.60 (0.36–0.98) 0.044
Lymphopenia 71.6 (78/109) 78.7 (148/188) 0.68 (0.39–1.17) 0.163
Abnormal creatinine 17 (17/100) 5.4 (8/169) 3.61 (1.54–8.47) 0.002
Abnormal creatinine clearance 64.4 (38/59) 52.3 (56/107) 1.64 (0.85–3.17) 0.133
Proteinuria (+) 50 (41/82) 30 (39/130) 2.33 (1.31–4.13) 0.003
aCLIgG (+) 40.7 (35/88) 29.7 (44/149) 1.62 (0.93–2.82) 0.087
Lupus anticoagulant (+) 58.5 (24/41) 45.9 (29/61) 1.66 (0.74–3.70) 0.211
CVD: cardiovascular disease; SLE: systemic lupus erythematosus; OR: odds ratio; CI: confidence interval; IQR: interquartile range; SD: standard deviation;
Y: years; MAS: multiple autoimmune syndrome; FDR: first-degree relatives; RA: rheumatoid arthritis; APS: antiphospholipid syndrome; AITD: autoimmune
thyroid disease; aCL: anticardiolipin antibodies.
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Table 4: Factors associated with CVD in patients with SLE∗.
Characteristic 𝛽 AOR 95% CI 𝑃
Dyslipidemia 0.971 2.64 1.32–5.28 0.005
Pleural effusion 0.751 2.12 1.17–3.84 0.013
Ever smoking 0.602 1.83 1.07–3.10 0.025
Coffee consumption 0.559 1.75 1.01–3.04 0.043
Renal involvement 0.476 1.61 0.94–3.84 0.081
CVD: cardiovascular disease; SLE: systemic lupus erythematosus; 𝛽: 𝛽 coefficient; AOR: adjusted odds ratio; 95% CI: 95% confidence interval.
∗Themodel was adjusted by gender and duration of the disease.
Table 5: Factors associatedwithCVD in patientswith SLE including
interaction between smoking and coffee consumption∗.
Characteristic 𝛽 AOR 95% CI 𝑃
APS 1.55 4.71 1.81–12.2 0.001
Dyslipidemia 1.07 2.92 1.54–5.55 0.001
Pleural effusion 0.78 2.19 1.20–3.98 0.011
Smoking and coffee 0.60 1.82 1.05–3.13 0.03
CVD: cardiovascular disease; SLE: systemic lupus erythematosus; 𝛽: 𝛽
coefficient; AOR: adjusted odds ratio; CI: confidence interval; APS: antiphos-
pholipid syndrome.
∗Adjusted by gender and duration of the disease including interaction
between smoking and coffee consumption. 𝑃-values persisted significant
despite the evaluation of the four possible combinations (i.e., smoking,
coffee, smoking and coffee, none) through the adjustment of themultivariate
model.
having a CVD event. In the PROFILE population, another
multicenter, multiethnic study population, Bertoli et al. [111]
found that smoking acted as an independent risk factor
associatedwith a 2-fold decrease in time to a CV event among
1,333 SLE patients over a 6.4-year follow-up period.
Several studies have evaluated the association between
coffee consumption and CVD in the general population with
controversial results. Two Dutch studies [112, 113] found
no association between coffee intake, high blood pressure,
and CVD. Despite the classification of coffee consumption
differed among studies, some results suggest that habitual
coffee consumption is associatedwith increased risk of hyper-
tension [114]. In the same way, Klag et al. [115] demonstrated
over many years of followup that coffee drinking is associated
with small increases in blood pressure but appears to play a
small role in the development of hypertension. When they
compared with nondrinkers at baseline, coffee drinkers had
a greater incidence of hypertension during follow-up (18.8%
versus. 28.3%; 𝑃 = 0.03). Relative risk (95% confidence inter-
val) of hypertension associated with drinking 5 or more cups
a day was 1.35 (0.87–2.08) for baseline intake and 1.60 (1.06–
2.40) for intake over followup. Other effects attributed to cof-
fee drinking are the increase in systemic vascular resistance,
increased serum cholesterol levels, arterial stiffness, plasma
rennin activity, epinephrine and norepinephrine, driving
an unfavorable effect on endothelial function in healthy
population [116]. On the other hand an Australia study [117]
detected a negative association between coffee, hypertension,
and MetS. Likewise, an increase in flow-mediated dilation
and a decrease in CRP levels related to coffee drinking have
been observed regardless of CAD [118, 119].
In order to isolate the interaction of smoking and coffee
consumption, two regression models were made in which
both the independent effect of coffee and smoking consump-
tion on CVD as well as their interaction remains significant,
demonstrating synergism between them (i.e., multiplicative
effect). Otherwise, coffee consumption has not been evalu-
ated systematically in SLE patients with CVD.However, since
there is not a universal accepted tool for assessing coffee
consumption, a bias concerning this variable is not precluded.
Furthermore, membership bias could also exist because
coffee consumption in Colombia is a well-defined tradition.
4.4. Traditional Risk Factors for CVD in SLE. Diverse lupus
cohorts had shown the influence of advanced age, dyslipi-
demia, obesity, hypertension, and hyperhomocysteinemia, as
classical risk factors for CVD [109, 120, 121]. Younger patients
with SLE have the greatest relative risk compared to their
healthy counterparts, but the absolute risk of CVD among
SLE patients increases with advancing age [8]. de Souza et
al. [58] observed that young Brazilian patients with SLE
presented higher prevalence of carotid plaque than controls.
Lo´pez-Jaramillo et al. [122] showed that the concentration
of proinflammatory cytokines is higher in the LA population
than in developed countries, suggesting a higher susceptibil-
ity to develop systemic low-degree inflammation at a given
level of abdominal obesity, which contributes to the burden
of CVD in this population. The inflammatory milieu of SLE
leads to deregulation of lipid metabolism pathways, which
contribute to the increased risk of atherosclerotic disease
among these patients [123, 124]. Five large cohort studies have
shown hypercholesterolemia as a risk factor for CVD in SLE
patients [98, 103, 125–127]. Our results confirm the role of
dyslipidemia as an independent risk factor for CVD in LA
patients with SLE [50, 52, 53, 58, 60, 62–64, 66, 80, 81, 83, 84,
89]. For more details see Table 6.
4.5. Nontraditional Risk Factors for CVD in SLE. It is well
known that while traditional CVD risk factors are undoubt-
edly important in increasing the CVD risk among SLE
patients, these do not fully account for the elevated risk of
CVD in this population [9]. Thereby, SLE-associated factors
play an important role in the premature atherosclerosis
process characteristic of these patients [128, 129]. Evidence
strongly suggests that atherosclerotic plaque is largely driven
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Figure 1: Flowchart of the systematic literature review. SLE: systemic lupus erythematosus, CVD: cardiovascular disease, LA: Latin America.
by inflammation and an active immunological response [130–
132] and points to SLE itself as an independent risk factor
for premature CAD [133, 134]. Nontraditional risk factors for
CVD in ADs may be classified into genetics, AD-related, and
miscellaneous [135, 136].
Family and twin studies have repeatedly supported a
role for heredity in CAD, particularly in young individuals.
Several genetic markers have been proposed as predisposing
factors for CVD in SLE patients [87, 137, 138]. The SLE-
associated risk factors represent a broad spectrum of con-
ditions related to the autoimmune nature of the disease. All
of these pathways may eventually converge into a shared
proatherogenic phenotype [139]. Table 6 summarizes the
state of the art of CVD risk factors in LA patients with SLE.
4.6. Assessment and Management of CV Risk in SLE Patients.
Physicians often face the question of how to personalize
treatment and prevention of CV events. Framingham risk
score (FRS) is widely used to stratify asymptomatic patients
into different CV risk categories in order to target the inten-
sity of primary medical intervention. This score is strongly
influenced by age and therefore has limited usefulness in
young patients with SLE [140]. Therefore, evaluation of only
traditional CAD risk factors in lupus patients may result
in the underestimation of their future overall CAD risk.
The contribution of inflammatory biomarkers should be
also considered to gain a complete picture of the CAD
risk in patients with underlying conditions that increase
inflammation such as SLE [141]. The Reynolds Risk score
incorporates CRP concentration in the riskmodel and reclas-
sifies approximately 50% of women in the 10-year FRS 5–
20% risk category into different risk categories [142]. Another
proposed approach corresponds to Systematic Coronary Risk
Evaluation that is recommended by the EULAR experts and
is widely used for CV assessment in patients with rheumatoid
arthritis and other forms of inflammatory arthritis [143].
Neither of these charts includes the broad variety of risk
factors that are disease-specific and could potentially explain
the increased burden due to CV events.Therefore, CV risk in
SLE patients is consistently underestimated with these scales.
Recently, Petri and Magder [144] proposed a data-driven
risk equation of CV risk in SLE, based on data collected
in a longitudinal cohort that can better estimate 10-year
CV risk than the Framingham equation. In this model an
integer score is given to each variable including age over 40,
male gender, systolic blood pressure over 140, TC over 160,
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Classic risk factors
MetS
Obesity
Smoking
Dyslipidemia
Advanced age
Menopausal status
Family history of CVD
Hyperhomocysteinemia
Sedentary lifestyle
Renal impairment
Hypertension
Male gender
T2DM/IR
HRT
Ancestry
HLA and non-HLA
SLE per se
Polyautoimmunity
Autoantibodies
Proinﬂammatory markers
Circulating ICs
Immune cells aberrations
Endothelial adhesion molecules
CD40/CD40L costimulatory molecules
Hyperprolactinemia
SLE disease activity and duration
Organ damage
Vasculopathy
Lupus nephritis
Endogenous dyslipidemia
Premature menopause
Medications
Sociodemographic factors
Hypovitaminosis D
Osteoporosis
Biomarkers
Others
∙ Aggressive treatment of disease activity, immunomodulatory drugs (AMs,CYC, and MMF).
∙ Monitoring and treatment of CV risk factors (traditional and nontraditional).
∙ Other medications: aspirin, statins, ACE-I, and AT-II blockers.
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Figure 2: Traditional and autoimmune-relatedmechanisms of cardiovascular disease in systemic lupus erythematosus. A complex interaction
between traditional and disease-specific traits leads to premature atherosclerotic process. Several risk factors (left) have been described since
The FraminghamHeart Study, known as classic risk factors, which over time conduce to endothelial dysfunction, subclinical atherosclerosis,
and CV event manifest. In the autoimmune setting (right), a broad spectrum of novel risk factors contribute to development of premature
vascular damage. This damage is represented by impaired endothelial function and early increased of Intima-Media Thickness which
are surrogates of the accelerated atherosclerosis process, which is perpetuated by a chronic proinflammatory milieu. The cornerstone of
management of CV risk include an aggressive treatment of disease activity, the continuous monitoring and treatment of modifiable CV
risk factors, as well as the use of other medications in order to diminish de CV burden. CVD: cardiovascular disease, SLE: systemic
lupus erythematosus, MetS: metabolic syndrome, T2DM: type 2 diabetes mellitus, IR: insulin resistance, HRT: hormone replacement
therapy, CIC: Circulating Immune complex, oxLDL/B2GPI complex: oxidized-low density lipoprotein/𝛽2 glycoprotein I, HDL: high density
lipoprotein,Auto-Ab: auto-antibodies, AMs: antimalarials, CYC: cyclophosphamide,AZA: azathioprine,MMF:mycophenolatemofetil, ACE-
I: angiotensin-converting enzyme inhibitors, AT-II blockers: angiotensin II receptor blockers.
smoking, T2DM, mean SLE disease activity index (SLEDAI),
history of lupus anticoagulant, and low mean C3. Using this
model, together in the absence of SLE-specific risk factors, the
estimated risk is higher than what would be projected based
on the FRS. Nevertheless, this model is not exempt: limita-
tions on, for example, HDL and LDL are not available at all
routine visits. Further validation of this model is warranted.
SLE entails a CVD equivalent to T2DM; thus, lower
lipid goals, aspirin use, and an aggressive monitoring are
required [145, 146]. Studies aimed to evaluate whether or not
traditional treatment regimens prevent or slow atheroscle-
rosis in SLE patients have been published [147]. The recent
randomized controlled Lupus Atherosclerosis Prevention
Study suggested that atorvastatin do not slow progression of
subclinical atherosclerosis [148].
There are several new mechanisms of action described
for antimalarials, many of them with beneficial effects in
the management of CV risk in patients with SLE [149, 150].
There is evidence that antimalarials reduce serum cholesterol
and LDL levels, elevate HDL cholesterol, and when taken
concomitantly with steroids can reduce serum cholesterol
[151]. Penn et al. [152] suggested that hydroxychloroquine use
is associatedwith a lower fasting glucose and a decrease in the
homeostasis model assessment-insulin resistance (HOMA-
IR) index. Rekedal et al. [153] showed that hydroxychloro-
quine initiation was associated with a significantly greater
reduction in HbA1c as compared to methotrexate initiation
among diabetic patients with rheumatic diseases. In addition,
beneficial effects of hydroxycloroquine on thrombosis forma-
tion have also been described. Multiple retrospective cohort
studies have shown a reduced incidence of thrombotic events
and improved overall survival in patients with SLE treated
with antimalarials [154–157].
The presence of low vitamin D levels has been associated
with disrupting self-tolerance. Therefore, it is tempting to
speculate that vitamin D might prove useful as a preventive
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Table 6: Traditional and nontraditional risk factors associated with cardiovascular disease and systemic lupus erythematosus in Latin
America.
Risk factor associated
with CVD Comments Reference(s)
Traditional
Hypertension
Hypertension influences the risk of death by CVD in SLE patients. [64, 89]
Hypertension acts as CVD subphenotype as well as a risk factor. [45, 49, 71, 88]
Patients with SLE were at increased risk of thrombosis when it is associated with
hypertension. [17, 80, 84]
Compared with patients without atherosclerotic plaque, those with plaque had
higher prevalence of hypertension. [54, 63, 66, 73]
Lupus patients with abnormal myocardial scintigraphic findings and hypertension,
as a risk factor for CAD, had a higher risk of abnormal findings on coronary
angiography.
[52, 53]
Patients with lupus had higher hypertension prevalence than controls with
noninflammatory disorders. [14, 68, 90]
T2DM
T2DM influence on abnormal myocardial perfusion in asymptomatic patients with
SLE. [53]
Alterations in glycemic profile were associated with traditional risk factors for CHD
and lupus characteristics, including CVD, damage index, and renal involvement. [17, 68, 81]
Patients with SLE and T2DM were at increased risk of thrombosis. This risk
remains elevated throughout the course of the disease. [16, 80]
T2DM is an independent risk factor for atherosclerotic plaque and CAC. [63, 71, 84]
Dyslipidemia
The main risk factor for death in SLE was heart involvement, which was influenced
by dyslipidemia. [50, 89]
High levels of TGL were associated with myocardial perfusion abnormalities and
endothelial dysfunction [52, 53, 83]
There was high prevalence of dyslipidemia as risk factor for thrombotic events. [60, 62, 80]
Alterations in lipid profile was a risk factor for premature CAC in young women
with SLE. [66, 84]
CAD was more prevalent in dyslipidemic women with SLE than controls. [64, 81]
Compared with patients without atherosclerotic plaque, those with plaque had high
level of TGL and LDL. [58, 63]
Male gender
Male gender was a risk factor for developing severe organ damage (CVD) and
mortality in SLE patients. [16, 17, 53, 60]
Males with SLE were at increased risk of thrombosis and CAC. This risk remains
elevated throughout the course of the disease. [80, 84, 85]
Patients had more peripheral vascular and gonadal involvement compared with
published data from non-Hispanic SLE populations. [76]
MetS
SLE patients had a high prevalence of MetS that directly contributes to increasing
inflammatory status and oxidative stress. [69]
MetS was associated with traditional risk factors for CHD and lupus characteristics,
including CVD, damage Index, and renal involvement. [68, 81]
Presence of MetS was related to CVD in SLE patients. [90, 94]
Obesity
Patients with SLE who had excess weight present distinct clinical-laboratory
findings, sociodemographic characteristics, and treatment options when compared
to normal weight patients.
[17, 71, 81]
Excess weight is associated with some traditional risk factors for CVD and SLE poor
prognosis. [58, 65, 68]
Increase weight influence on abnormal myocardial perfusion in asymptomatic
patients with SLE. [53, 64]
SLE patients with high BMI have increased QT interval parameters when compared
to controls. This prolongation may lead to an increased CV risk. [55]
Major values in BMI were related with the presence of CAD and carotid plaque. [58, 63, 64]
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Table 6: Continued.
Risk factor associated
with CVD Comments Reference(s)
Smoking
Smoking is an important determinant in the occurrence of thrombotic (central
and/or peripheral, arterial and/or venous) events in SLE patients. [18, 69, 81]
Smoking was an independent risk factor for atherosclerotic plaque and thrombosis. [63, 68, 80]
Smoking habit influence on abnormal myocardial perfusion in asymptomatic
patients with SLE. [53]
Smoking was a risk factor for premature CAC in young women with SLE. [66, 84]
CAD was more prevalent in women with SLE. [64, 85, 86]
Advance age
Several traditional risk factors, including age, appear to be important contributors
to atherosclerotic CV damage. [16, 71]
The presence of CVD has been associated with older age. [16, 59]
Age was directly related with atherosclerotic plaque formation. [63]
Menopausal status
High percentage of SLE patients with abnormal angiographic findings was in
postmenopausal status. [52]
There is high prevalence of premature menopausal status as a risk factor for CVD. [60]
Postmenopausal status was a risk factor for premature CAC in young women with
SLE. [66, 68, 84]
Postmenopausal women had a higher prevalence of subclinical AT and abnormal
myocardial perfusion in asymptomatic patients with SLE. [53, 63]
Family history of CVD
Familial history of CVD was an independent risk factor for atherosclerotic process. [17, 63, 68]
Family history of CVD was a risk factor for premature CAC in young women with
SLE. [66, 84]
Family history of CVD influence on abnormal myocardial perfusion in
asymptomatic patients with SLE. [53]
HRT
HRT use was not associated with the occurrence of vascular arterial events in the
LUMINA patients. HRT use in women with SLE should be individualized, but data
suggest its use may be safe if aPL antibodies are not present or vascular arterial
events have not previously occurred.
[17]
Hyperhomocysteinemia Hyperhomocysteinemia was a risk factor for CAC in SLE patients. [84]
The presence of polyautoimmunity and hyperhomocysteinemia was risk factors for
thrombotic events. [41]
Nontraditional
Genetic determinants
Ancestry
There are several differences regarding clinical (including CVD), prognostic,
socioeconomic, educational, and access to medical care features in GLADEL cohort
according to ancestry (White, Mestizo, and African-LA).
[14]
Non-HLA
An SNP in FGG rs2066865 demonstrated association with arterial thrombosis risk
in Hispanic Americans patients with SLE. [87]
The CRP GT20 variant is more likely to occur in African-American and Hispanic
SLE patients than in Caucasian ones, and SLE patients carrying the GT20 allele are
more likely to develop vascular arterial events (LUMINA multiethnic cohort).
[86]
SLE-associated
Poliautoimmunity
The presence of APS was the major independent contributor to the development of
severe organ damage in Brazilian patients with SLE. [54]
APS and its characteristic antibodies may contribute to the development of
thrombotic events in Brazilian and Mexican lupus patients. [57, 78]
APS had high impact in CVD and survival in Brazilian lupus patients. [42]
Polyautoimmunity (APS) may suggest concerted pathogenic actions with other
autoantibodies in the development of thrombotic events in Mexican patients with
SLE.
[78]
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Table 6: Continued.
Risk factor associated
with CVD Comments Reference(s)
SLE per se
SLE diagnosis was significantly associated with carotid plaque formation and
development of CV event in Brazilian patients with SLE. [58]
High percentage of patients with abnormal angiographic findings had higher ACR
criteria number for SLE Brazilian patients with SLE. [52]
Autoantibodies
One of the independent predictors of vascular events in a multiethnic US cohort
(LUMINA) was the presence of any aPL antibody. [17]
anti-𝛽2GPI antibodies were strongly associated with thrombosis in patients with
Mexicans with SLE. The decrease of anti-𝛽2GPI levels at the time of thrombosis
may indicate a pathogenic role.
[77]
The higher frequency of aPT found in Mexican patients with SLE with thrombosis
may suggest concerted pathogenic actions with other autoantibodies in the
development of thrombotic events.
[78]
Patients with aCL antibodies seem to be at an increased risk for arterial and venous
thrombotic events in Puerto Ricans and Chilean patients with SLE. [92, 96]
There was correlation between lupus anticoagulant and thrombotic events in
Brazilian lupus patients. [50]
aCL antibodies were associated with thrombotic events, mainly in high titers in
Chilean SLE patients. [96]
aCL antibodies were significantly associated with CV events and showed an
association with echocardiographic abnormalities in Brazilian patients with SLE. [51]
Mexican patients had more peripheral vascular compared with published data from
non-Hispanic SLE populations. [76]
Immune cells
aberrations
Complement fixing activity of aCL antibodies seems to be relevant in thrombotic
venous events in Brazilian patients with SLE. [57]
Inflammatory markers
Increased ESR was independently associated with MetS in Puerto Ricans lupic
patients. [94]
One of the independent predictors of vascular events in a multiethnic US cohort
(LUMINA) was elevated serum levels of CRP. [16, 17]
Endogenous
dyslipidemia
HDL distribution and composition (−HDL2b, +HDL3b, and +HDL3c) were
abnormal in noncomplicated Mexican SLE patients. [79]
Low HDL levels and increased TGL levels were associated with atherosclerosis by
cIMT measurement in Colombian lupic patients. [95]
SLE patients have a lipid profile abnormality in Brazilian patients with SLE. This
pattern of dyslipoproteinemia may increase the risk of developing CAD. [47]
Disease activity
Disease activity (SLAM) is an important determinant in the occurrence of
thrombotic (central and/or peripheral, arterial, and/or venous) events in the
LUMINA cohort.
[18]
SLEDAI scores were positively correlated with BMI andWC in Brazilian population
with SLE. [69]
Higher disease activity was independently associated with MetS and thrombosis in
Puerto Ricans and Mexican SLE patients. [80, 94]
Higher score of SLICC was associated with atherosclerotic plaque in Brazilian SLE
patients. [58]
High scores in diseases activity index (SLEDAI and SLICC) were associated with
myocardial perfusion abnormalities in Brazilian SLE patients. [52]
Brazilian SLE patients have a lipid profile abnormality which is aggravated by
disease activity and may reside in a defect of VLDL metabolism. [47]
Disease activity was predictor of CAC in Mexican SLE patients. [84]
Higher disease activity was independently associated with MetS in Puerto Ricans
patients with SLE. [94]
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Table 6: Continued.
Risk factor associated
with CVD Comments Reference(s)
Organ damage
Baseline and accrued damage increase mortality risk (including due to CVD) in
Brazilian patients with SLE. [61]
Mexican patients had more peripheral vascular involvement (measured by SDI),
compared with published data from non-Hispanic SLE populations. [76]
In Brazilian SLE patients, MetS was associated with both traditional risk factors for
CHD and lupus characteristics including damage index. [68]
There was a correlation between IMT and revised damage index (SLICC) in
Brazilian SLE patients. [58]
Atherosclerotic CV damage in SLE is multifactorial, and disease-related factors
(including CRP levels and SDI at baseline) appear to be important contributors to
such an occurrence (LUMINA multiethnic cohort).
[16]
Long duration
Longer duration of SLE was associated with atherosclerotic plaque and CV events in
Brazilian population. [58, 59]
A correlation between IMT and duration of the disease was found in Brazilian
patients with SLE. [63]
Disease duration was independent predictor for premature CAC in young Brazilian
women with SLE. [66]
Medications
PDN > 10mg/day was independently associated with MetS in Puerto Ricans SLE
patients. [94]
In Brazilian SLE patients, there was a correlation between IMT and the duration of
PDN use. [63]
IHD was observed in two types of Mexican SLE patients: those with long-term
steroid therapy and those with frank episodes of vasculitis. [73]
Vasculopathy
Current vasculitis was associated with abnormal myocardial scintigraphy in
Brazilian patients with SLE. [53]
Puerto Ricans patients with SLE and RP seem to be at increased risk for arterial and
venous thrombotic events. [92]
IHD was observed in two types of Mexican SLE patients: those with long-term
steroid therapy and those with frank episodes of vasculitis. [73]
Renal involvement
In Brazilian SLE patients, MetS was associated with traditional risk factors for CHD
and lupus characteristics, including damage index and renal involvement (nephritic
syndrome).
[68]
Miscellaneous
BMD Decreased BMD was an independent predictor for premature CAC in Brazilianyoung women with SLE. [66]
Sociodemographic
factors
A low education and monthly income were associated with MetS in Mexican
patients with SLE and RA. [81]
aCL: anticardiolipins antibodies; ACR:AmericanCollege of Rheumatology; anti-𝛽2GPI: anti-beta2 glycoprotein 1 antibodies; aPT: antiprothrombin antibodies;
aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; AT: atherosclerosis; BMD: bone mineral density; BMI: body mass index; CAC: coronary
artery calcification; CAD: coronary artery disease; cIMT: carotid Intimal Medial Thickness; CHD: coronary heart disease; CRP: C-reactive protein; CV:
cardiovascular; CVD: cardiovascular disease; ESR: erythrocyte sedimentation rate; GLADEL: Grupo Latino Americano De Estudio de Lupus; HDL: high-
density lipoprotein cholesterol; HRT: hormone replacement therapy; IHD: ischemic heart disease; IMT: intimal media thickness; LA: Latin America; LDL: low-
density lipoprotein cholesterol; LUMINA: LUpus in MInorities: NAture versus nurture cohort; MetS: metabolic syndrome; PDN: prednisolone; RP: Raynaud’s
phenomenon; T2DM: type 2 diabetes mellitus; TGL: triglycerides; SLAM: Systemic Lupus Activity Measure; SLE: systemic lupus erythematosus; SLEDAI:
systemic lupus erythematosus disease activity index; SLICC: Systemic Lupus International Collaborating Clinics score; SDI: SLICC damage index; SNP: single-
nucleotide polymorphism; VLDL: very low-density lipoprotein cholesterol; WC: waist circumference.
agent by reducing the risk of developing an autoimmune
response [158]. In addition, vitamin D has been found to
have antithrombotic properties improving the risk of CVD.
Vitamin D deficiency has been linked to the development
of atherosclerosis. As a corollary, the use of vitamin D may
be useful to improve microvascular endothelial function
[158].
5. Limitations of the Study
As a cross-sectional study, it is placed at level 4 of evi-
dence according to Oxford Evidence Based Medicine [40].
Although the study sample size is not negligible, it would have
been more valuable to have had an appropirate followup to
establish valid associations between CVD, novel risk factors,
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and SLE.This, in turn, could have improved both internal and
external validities.
The diversity of parameters defining CVD in SLE pre-
cluded homogenization of analysis and assessment in the
systematic review. Often, one or two CVD subphenotypes
were assessed as primary outcomes butmanydid not consider
general CVD compromise. Therefore, it was not possible to
perform a meta-analysis and to establish true measures of
association such as odds ratios. Finally, we acknowledge that
publication bias may exist.
6. Final Remarks and Conclusions
CVD is a major cause of morbidity and mortality in SLE
patients. SLE and CVD share common pathophysiology
mechanisms (i.e., systemic and chronic inflammation) with
secondary accelerated atherosclerosis. Since traditional risk
factors do not completely explain the high rates of CVD in
patients with SLE, novel risk factors related to autoimmunity
are now recognized. In the current study classical risk
factors such as dyslipidemia, coffee consumption, and smok-
ing habit are highlighted, and SLE-related factors (i.e., SLE-
antiphospholipid syndrome polyautoimmunity, pleural effu-
sion, and renal involvement) are confirmed. In addition, sev-
eral factors associated with CVD in LA patients with SLE
were reviewed. Altogether, our results should encourage pre-
ventive population strategies for CVD in patients with SLE
[106, 159], aimed at facilitating the suppression of cigarette
smoking and coffee consumption as well as to the tight con-
trol of dyslipidemia and other modifiable risk factors.
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